Fc Fusion Protein Market: Industry Trends and Global Forecasts - Distribution by Target Indications, Type of Fusion Molecule, Route of Administration and Key Geographical Regions

List of Tables

GLOBAL FC FUSION PROTEIN MARKET: OVERVIEW

As per Roots Analysis, the global Fc fusion protein market valued at USD 15.5 billion in the current year is anticipated to grow at a CAGR of 10% during the forecast period.

The market sizing and opportunity analysis has been segmented across the following parameters:

Target Indications

Neutropenia
Graft Versus Host Disease
Breast Cancer
Rheumatoid Arthritis
Non-Small Cell Lung Cancer
Neovascular (Wet) Age-related Macular Degeneration (AMD)
Hemophilia A
Neuromyelitis Optica Spectrum Disorders
Systemic Lupus Erythematosus

Type of Fusion Molecule

Antibody
Cytokine
Growth Factor
Receptor ECD
Others

Route of Administration

Subcutaneous
Intravenous
Intravitreal

Key Geographical Regions

North America
Europe
Asia-Pacific
Rest of the World

GLOBAL FC FUSION PROTEIN MARKET: GROWTH AND TRENDS

Since the approval of Enbrel(R) (a CD4-Fc fusion protein for the treatment of rheumatoid arthritis) in 1998, Fc fusion protein therapies have become a prominent class of therapeutics. At present, 13 Fc fusion protein-based drugs are commercially available, and approximately 50 additional molecules are in development for a range of disease indications. These therapies combine the advantageous pharmacological properties of biologically active ligands with the unique characteristics of the crystallizable fragment (Fc) domain of immunoglobulin G (IgG). Moreover, due to their ability to prolong the serum half-life of biologically active proteins, these disease-modifying therapies are utilized in a variety of therapeutic areas. Some of these include oncological, neurological, respiratory, and rare genetic disorders.

Currently, numerous drug developers are actively involved in the development of novel Fc fusion therapies with improved efficacy. In fact, the research efforts by developers in this area are centered on enhancing the stability and solubility of the pharmacologically active component, ultimately aiming to boost its therapeutic potential. Consequently, the Fc fusion therapies market is expected to witness healthy market growth during the forecast period.

GLOBAL FC FUSION PROTEIN MARKET: KEY INSIGHTS

The report delves into the current state of global Fc fusion protein market and identifies potential growth opportunities within industry. Some key findings from the report include:

Presently, around 40 players from across the world, are engaged in evaluating the potential benefits of Fc fusion therapeutics for the treatment of a wide range of disease indications.
The pipeline features 115+ drug therapies being evaluated either as monotherapies or in combination with other interventions across different stages of development; most of these are designed for parenteral administration.
Majority of the approved therapies and late-stage candidates are intended for the treatment of various oncological disorders, genetic disorders, hematological disorders and immunological disorders.
Given the therapeutic benefits of fc fusion, these interventions are primarily evaluated as monotherapies; examples of late-stage drugs being investigated as monotherapy include ACE-011 and RC18.
Around 50% of the fc fusion therapeutics are meant for subcutaneous administration; these can be self-administered by the patients using different drug delivery systems.
Over two million patients have been enrolled in the clinical studies being conducted for the evaluation of close to 120 fc fusion-based therapy candidates, across various geographies.

Several organizations have extended financial support to aid research efforts in this domain; currently, the focus, in terms of funds disbursed, is primarily in support of investigations of drugs for non-SBIR / STTR purposes.
The number of grants awarded to stakeholders in this domain have increased in the past few years; more than 60% of the total amount was awarded for research projects.
The field has witnessed the involvement of various administering institutes of the NIH; of all the institutes, participation of the NCI, NIAID, and NHLBI has been relatively more prominent.
Over time, the intellectual property related to Fc fusion therapeutics has grown at a commendable pace, with patents being filed by both industry and non-industry players.
Number of patents filed / granted in this domain have increased at a CAGR of 17% during the given time period, with majority of the patents filed / granted in the past two years.
In addition to industry players, several academic organizations, such as Stanford University and INSERM have also filed patents related to fc fusion therapeutics.
The high value patents focus on the modification of Fc region with different fusion molecules, such as receptor ECD, enzyme and peptide.
Published scientific literature is indicative of the ongoing pace of research in this field; the focus of past and ongoing studies seems to be fixated on the development of anti-cancer therapeutics.
The past few years have seen a steady rise in the number of publications related to fc fusion therapeutics; these include articles highlighting the type of biological moieties fused with the Fc region of the antibodies.
Majority (~70%) of the published articles are related to the research studies focused on evaluating the therapeutic potential of Fc fusion proteins across various oncological and blood disorders.
Articles related to Fc fusion therapeutics have been published in several high impact journals; however, PLoS One and MAbs have emerged as the key journals with over 30 articles.
With multiple pipeline candidates in the mid to late stages of development, these interventions are primarily targeting oncological disorders; majority of these are Fc protein engineered antibodies.
A number of marketed drugs, such as Fasenra, Gazyva, Margenza and Skyrizi, are now being evaluated for their efficacy across other oncological indications as well.
Majority (~60%) of the late-stage candidates are targeting oncological indications, including solid tumors, non-Hodgkin lymphoma, and non-small cell lung cancer.
Driven by an increasing number of late-stage therapies in the pipeline, the future opportunity, in terms of revenues, is anticipated to grow at an annualized rate of nearly 10%.

The estimated market opportunity is expected to be well-distributed across different types of therapies, target indications, type of fusion molecules, routes of administration and key geographic regions.

Example Players in the Drug Discovery Platforms Market

Abzena
Creative Biolabs
Distributed Bio (Subsidiary of Charles River)
ImmunoPrecise Antibodies
IONTAS
LakePharma
Leading Biology
Sino Biological
XOMA

GLOBAL FC FUSION PROTEIN MARKET

Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the global Fc fusion protein market, focusing on key market segments, including [A] target indications, [B] type of fusion molecule, [C] route of administration and [D] key geographical regions.
Market Landscape: A comprehensive evaluation of Fc fusion therapeutics, considering various parameters, such as [A] phase of development of lead candidates, [B] type of fusion molecule, [C] target gene, [D] therapeutic area(s), [E] target disease indication(s), [F] type of therapy, [G] route of administration and [H] dosing frequency. Additionally, a detailed evaluation of the drug developer(s), based on [A] year of establishment, [B] company size, and [C] location of headquarters.
Company Profiles: In-depth profiles of companies engaged in the development of Fc fusion therapeutics, focusing on [A] company overview, [B financial information (if available), [C] product portfolio and [D] recent developments and an informed future outlook.
Clinical Trial Analysis: A detailed analysis of clinical studies of various Fc fusion therapeutics, based on several relevant parameters, such as [A] trial registration year, [B] trial phase, [C] study design, [D] type of masking, [E] type of intervention model, [F] emerging focus area, [G] leading industry sponsors / collaborators, [H] popular indications, [I] popular interventions and [J] regional distribution of trials.
Grant Analysis: An in-depth analysis of grants that have been awarded to research institutes engaged in conducting projects related to Fc fusion therapeutics, based on various relevant parameters, such as [A] year of grant award, [B] amount awarded, [C] administering institute center, [D] support period, [E] type of grant application, [F] purpose of grant award, [G] activity code and [H] emerging focus areas.
Publication Analysis: A comprehensive analysis of close to 1,135 peer-reviewed scientific articles related to Fc fusion therapeutics, based on [A] year of publication, [B] emerging focus areas, [C] target therapeutic area, [D] leading authors and [E] key journals.
Patent Analysis: An in-depth analysis of patents filed / granted related to Fc fusion therapeutics, based on various relevant parameters, such as [A] publication year, [B] geography, [C] CPC symbols, [D] emerging focus areas, [E] type of applicant, [F] leading industry players and [G] patent valuation analysis.
Partnerships and Collaborations: An insightful analysis of the deals inked by stakeholders in this domain, based on several parameters, such as [A] year of partnership, [B] type of partnership, [C] focus area, [D] type of partner, [E] most active players (in terms of the number of partnerships signed) and [F] geographical distribution of partnership activity.
Case Study: A detailed discussion on the Fc protein engineered and glycoengineered antibodies that are either marketed or being developed based on multiple of relevant parameters, such as [A] phase of development, [B] target disease indication, [C] therapeutic area, [D] type of Fc engineering, [E] impact of Fc engineering, [F] route of administration and [G] type of therapy.

KEY QUESTIONS ANSWERED IN THIS REPORT

How many companies are currently engaged in this market?
Which are the leading companies in this market?
What factors are likely to influence the evolution of this market?
What is the current and future market size?
What is the CAGR of this market?
How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

Complimentary PPT Insights Packs
Complimentary Excel Data Packs for all Analytical Modules in the Report
15% Free Content Customization
Detailed Report Walkthrough Session with Research Team
Free Updated report if the report is 6-12 months old or older

Product Code: RA100296

1. PREFACE

1.1. Scope of the Report
1.2. Research Methodology
- 1.2.1. Research Assumptions
- 1.2.2. Project Methodology
- 1.2.3. Forecast Methodology
- 1.2.4. Robust Quality Control
- 1.2.5. Key Considerations
  - 1.2.5.1. Demographics
  - 1.2.5.2. Economic Factors
  - 1.2.5.3. Government Regulations
  - 1.2.5.4. Supply Chain
  - 1.2.5.5. COVID Impact / Related Factors
  - 1.2.5.6. Market Access
  - 1.2.5.7. Healthcare Policies
  - 1.2.5.8. Industry Consolidation
1.3 Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

3.1. Overview of Fc Fusion Therapeutics
3.2. Components of Fc Fusion Therapeutics
3.3. Mechanism of Action
3.4. Types of Fc Fusion Therapeutics
- 3.4.1. Antibody-based Fc Fusion Therapeutics
- 3.4.2. Cytokine-based Fc Fusion Therapeutics
- 3.4.3. Enzyme-based Fc Fusion Therapeutics
- 3.4.4. Peptide-based Fc Fusion Therapeutics
- 3.4.5. Receptor ECD-based Fc Fusion Therapeutics
3.5. Applications of Fc Fusion Therapeutics
3.6. Advantages of Fc Fusion Therapeutics over Other Biological Moieties
3.7. Future Perspectives

4. PIPELINE REVIEW: MARKETED AND CLINICAL DRUGS

4.1. Analysis Methodology and Key Parameters
4.2. Fc Fusion Therapeutics: Drug Pipeline
4.3. Fc Fusion Therapeutics: Pipeline Analysis
- 4.3.1. Analysis by Phase of Development
- 4.3.2. Analysis by Type of Fusion Molecule
- 4.3.3. Analysis by Target Gene
- 4.3.4. Analysis by Therapeutic Area(s)
- 4.3.5. Analysis by Target Disease Indication(s)
- 4.3.6. Analysis by Type of Therapy
- 4.3.7. Analysis by Route of Administration
- 4.3.8. Analysis by Dosing Frequency
4.4. Fc Fusion Therapeutics: List of Drug Developers
- 4.4.1. Analysis by Year of Establishment
- 4.4.2. Analysis by Company Size
- 4.4.3. Analysis by Location of Headquarters
- 4.4.4. Leading Developers
- 4.4.5. Grid Analysis: Distribution by Phase of Development, Company Size and Location of Headquarters

5. COMPANY PROFILES

5.1. Chapter Overview
5.2. Alphamab Oncology
- 5.2.1. Company Overview
- 5.2.2. Financial Information
- 5.2.3. Product Portfolio
- 5.2.4. Recent Developments and Future Outlook
5.3. Amgen
- 5.3.1. Company Overview
- 5.3.2. Financial Information
- 5.3.3. Product Portfolio
- 5.3.4. Recent Developments and Future Outlook
5.4. Acceleron Pharmaceuticals
- 5.4.1. Company Overview
- 5.4.2. Financial Information
- 5.4.3. Product Portfolio
- 5.4.4. Recent Developments and Future Outlook
5.5. Bristol Myers Squibb
- 5.5.1. Company Overview
- 5.5.2. Financial Information
- 5.5.3. Product Portfolio
- 5.5.4. Recent Developments and Future Outlook
5.6. Sanofi
- 5.6.1. Company Overview
- 5.6.2. Financial Information
- 5.6.3. Product Portfolio
- 5.6.4. Recent Developments and Future Outlook

6. CLINICAL TRIAL ANALYSIS

6.1. Analysis Methodology and Key Parameters
6.2. Fc Fusion Therapeutics: List of Clinical Trials
- 6.2.1. Analysis by Trial Registration Year
- 6.2.2. Analysis by Trial Phase
- 6.2.3. Analysis by Study Design
- 6.2.4. Analysis by Type of Masking
- 6.2.5. Analysis by Type of Intervention Model
- 6.2.6. World Cloud: Emerging Focus Areas
- 6.2.7. Analysis by Trial Registration Year and Geography
- 6.2.8. Analysis by Type of Sponsor
- 6.2.9. Leading Industry Players: Analysis by Number of Trials Registered
- 6.2.10. Leading Non-Industry Players: Analysis by Number of Trials Registered
- 6.2.11. Popular Indications: Analysis by Number of Registered Trials
- 6.2.12. Popular Interventions: Analysis by Number of Registered Trials
- 6.2.13. Geographical Analysis by Number of Registered Trials
- 6.2.14. Geographical Analysis by Number of Patients Enrolled

7. ACADEMIC GRANT ANALYSIS

7.1. Analysis Methodology and Key Parameters
7.2. Fc Fusion Therapeutics: Analysis of Academic Grants
- 7.2.1. Analysis by Year of Grant Award
- 7.2.2. Analysis by Amount Awarded
- 7.2.3. Analysis by Administering Institute Center
- 7.2.4. Analysis by Support Period
- 7.2.5. Analysis by Type of Grant Application
- 7.2.6. Analysis by Purpose of Grant Award
- 7.2.7. Analysis by Activity Code
- 7.2.8. Word Cloud Analysis: Emerging Focus Areas
- 7.2.9. Popular NIH Departments: Analysis by Number of Grants
- 7.2.10. Prominent Program Officers: Analysis by Number of Grants
- 7.2.11. Popular Recipient Organizations: Analysis by Number of Grants

8. PUBLICATION ANALYSIS

8.1. Analysis Methodology and Key Parameters
8.2. Fc Fusion Therapeutics: Recent Publications
8.3. Analysis by Year of Publication
8.4. Word Cloud Analysis: Emerging Focus Areas
8.5. Analysis by Target Therapeutic Area
8.6. Leading Authors: Analysis by Number of Publications
8.7. Key Journals: Analysis by Number of Publications

9. PATENT ANALYSIS

9.1. Analysis Methodology and Key Parameters
9.2. Fc Fusion Therapeutics: Patent Analysis
- 9.2.1. Analysis by Publication Year
- 9.2.2. Analysis by Type of Patent
- 9.2.3. Analysis by Geographical Location
- 9.2.4. Analysis by Patent Age
- 9.2.5. Analysis by CPC Symbols
- 9.2.6. Word Cloud Analysis: Emerging Focus Areas
- 9.2.7. Leading Patent Assignees: Analysis by Number of Patents
- 9.2.8. Leading Industry Players: Analysis by Number of Patents
- 9.2.9. Leading Non-Industry Players: Analysis by Number of Patents
- 9.2.10. Fc Fusion Therapeutics: Patent Benchmarking Analysis
- 9.2.11. Fc Fusion Therapeutics: Patent Valuation Analysis

10. PARTNERSHIPS AND COLLABORATIONS

10.1. Analysis Methodology and Key Parameters
10.2. Partnership Models
10.3. Fc Fusion Therapeutics: List of Partnerships and Collaborations
- 10.3.1. Analysis by Year of Partnership
- 10.3.2. Analysis by Type of Partnership
- 10.3.3. Analysis by Type of Partnership and Type of Fusion molecule
- 10.3.4. Analysis by Year of Partnership and Type of Partner
- 10.3.5. Analysis by Type of Partnership and Type of Partner
- 10.3.6. Most Active Players: Analysis by Number of Partnerships
- 10.3.7. Regional Analysis
  - 10.3.7.1. Intercontinental and Intracontinental Agreements

11. MARKET SIZING AND OPPORTUNITY ANALYSIS

11.1. Forecast Methodology and Key Assumptions
11.2. Global Fc Fusion Therapeutics Market, Till 2035
11.3. Global Fc Fusion Therapeutics Market, Till 2035: Distribution by Target Indication
11.4. Global Fc Fusion Therapeutics Market, Till 2035: Distribution by Type of Fusion Molecule
11.5. Global Fc Fusion Therapeutics Market, Till 2035: Distribution by Type of Therapy
11.6. Global Fc Fusion Therapeutics Market, Till 2035: Distribution by Route of Administration
11.7. Global Fc Fusion Therapeutics Market, Till 2035: Distribution by Geography
11.8. Fc Fusion Therapeutics: Individual Product Sales Forecasts
- 11.8.1. ABP 938 (Amgen)
- 11.8.2. Alprolix(R) (Sanofi)
- 11.8.3. AnBaiNuo(R) (Hisun Pharmaceuticals)
- 11.8.4. Arcalyst(R) (Kiniska Pharmaceuticals)
- 11.8.5. BIVV001 (Sanofi)
- 11.8.6. CD24Fc (Merck)
- 11.8.7. Eloctate(R) (Biogen)
- 11.8.8. Eylea(TM) (Regeneron Pharmaceuticals)
- 11.8.9. FRSW107 (Zhengzhou Gensciences)
- 11.8.10. KN035 (Alphamab Oncology)
- 11.8.11. KN046 (Alphamab Oncology)
- 11.8.12. Lumitin(R) (Chengdu Kanghong Biotech)
- 11.8.13. Reblozyl(R) (Bristol-Myers Squibb)
- 11.8.14. RyzneutaTM (Evive Biotech)
- 11.8.15. Strensiq(R) (AstraZeneca)
- 11.8.16. Telitacicept (RemeGen)

12. CASE STUDY: FC PROTEIN ENGINEERED AND GLYCOENGINEERED ANTIBODIES

12.1. Fc Protein Engineered and Glycoengineered Antibodies: Drug Pipeline
- 12.1.1. Analysis by Phase of Development
- 12.1.2. Analysis by Target Disease Indication
- 12.1.3. Analysis by Therapeutic Area
- 12.1.4. Analysis by Type of Fc Engineering
- 12.1.5. Analysis by Impact of Fc Engineering
- 12.1.6. Analysis by Route of Administration
- 12.1.7. Analysis by Type of Therapy
12.2. Fc Protein Engineered and Glycoengineered Antibodies: List of Developers
- 12.2.1. Analysis by Year of Establishment
- 12.2.2. Analysis by Company Size
- 12.2.3. Analysis by Location of Headquarters

13. CONCLUSION

14. APPENDIX 1: TABULATED DATA

15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

Product Code: RA100296

List of Tables

Table 4.1 Fc Fusion Therapeutics: Drug Pipeline
Table 4.2 Fc Fusion Therapeutics: List of Drug Developers
Table 5.1 Fc Fusion Therapeutics: List of Companies Profiled
Table 5.2 Drug Profile: KN015
Table 5.3 Drug Profile: KN046
Table 5.4 Drug Profile: KN035
Table 5.5 Drug Profile: KN058
Table 5.6 Drug Profile: KN055
Table 5.7 Drug Profile: KN019
Table 5.8 Alphamab Oncology: Recent Developments and Future Outlook
Table 5.9 Drug Profile: AMG 386
Table 5.10 Drug Profile: AMG 592
Table 5.11 Drug Profile: ABP 938
Table 5.12 Drug Profile: Enbrel(R)
Table 5.13 Drug Profile: Nplate(R)
Table 5.14 Amgen: Recent Developments and Future Outlook
Table 5.15 Drug Profile: ACE-1334
Table 5.16 Drug Profile: ACE-011
Table 5.17 Acceleron Pharmaceuticals: Recent Developments and Future Outlook
Table 5.18 Drug Profile: AVID200
Table 5.19 Drug Profile: Orencia(R)
Table 5.20 Drug Profile: Nulojix(R)
Table 5.21 Drug Profile: REBLOZYL(R)
Table 5.22 Bristol-Myers Squibb: Recent Developments and Future Outlook
Table 5.23 Drug Profile: Alprolix(R)
Table 5.24 Drug Profile: BIVV001
Table 5.25 Drug Profile: Zaltrap(R)
Table 5.26 Sanofi: Recent Developments and Future Outlook
Table 6.1 Fc Fusion Therapeutics: List of Clinical Trials
Table 10.1 Fc Fusion Therapeutics: List of Partnerships and Collaborations
Table 12.1 Fc Protein Engineered and Glycoengineered Antibodies: Drug Pipeline
Table 12.2 Fc Protein Engineered and Glycoengineered Antibodies: List of Drug Developers
Table 14.1 Fc Fusion Therapeutics: Distribution by Phase of Development
Table 14.2 Fc Fusion Therapeutics: Distribution by Type of Fusion Molecule
Table 14.3 Fc Fusion Therapeutics: Distribution by Target Gene
Table 14.4 Fc Fusion Therapeutics: Distribution by Therapeutic Area(s)
Table 14.5 Fc Fusion Therapeutics: Distribution by Target Disease Indication(s)
Table 14.6 Fc Fusion Therapeutics: Distribution by Type of Therapy
Table 14.7 Fc Fusion Therapeutics: Distribution by Route of Administration
Table 14.8 Fc Fusion Therapeutics: Distribution by Dosing Frequency
Table 14.9 Fc Fusion Therapeutics: Distribution by Year of Establishment
Table 14.10 Fc Fusion Therapeutics: Distribution by Company Size
Table 14.11 Fc Fusion Therapeutics: Distribution by Location of Headquarters
Table 14.12 Fc Fusion Therapeutics: Distribution by Leading Developers
Table 14.13 Amgen: Annual Revenues, Since 2016 (USD Billion)
Table 14.14 Acceleron Pharmaceuticals: Annual Revenues, Since 2016 (USD Billion)
Table 14.15 Bristol Myers Squibb: Annual Revenues, Since 2016 (USD Billion)
Table 14.16 Sanofi: Annual Revenues, Since 2016 (USD Billion)
Table 14.17 Clinical Trial Analysis: Distribution by Trial Registration Year
Table 14.18 Clinical Trial Analysis: Distribution by Trial Phase
Table 14.19 Clinical Trial Analysis: Distribution by Study Design
Table 14.20 Clinical Trial Analysis: Distribution by Type of Masking
Table 14.21 Clinical Trial Analysis: Distribution by Type of Intervention Model
Table 14.22 Clinical Trial Analysis: Distribution by Trial Registration Year and Geography
Table 14.23 Clinical Trial Analysis: Distribution by Type of Sponsor
Table 14.24 Leading Industry Players: Distribution by Number of Trials Registered
Table 14.25 Leading Non-Industry Players: Distribution by Number of Trials Registered
Table 14.26 Popular Indications: Analysis by Number of Registered Trials
Table 14.27 Popular Interventions: Analysis by Number of Registered Trials
Table 14.28 Popular Indications: Distribution by Number of Registered Trials
Table 14.29 Popular Interventions: Distribution by Number of Registered Trials
Table 14.30 Clinical Trial Analysis: Geographical Distribution by Number of Registered Trials
Table 14.31 Clinical Trial Analysis: Geographical Distribution by Number of Patients Enrolled
Table 14.32 Grant Analysis: Cumulative Trend by Year of Grant Award, Since 2010
Table 14.33 Grant Analysis: Cumulative Distribution by Amount Awarded (USD Million), Since 2010
Table 14.34 Grant Analysis: Distribution by Administering Institute Center
Table 14.35 Grant Analysis: Distribution by Support Period
Table 14.36 Grant Analysis: Distribution by Type of Grant Application
Table 14.37 Grant Analysis: Distribution by Purpose of Grant Award
Table 14.38 Grant Analysis: Distribution by Activity Code
Table 14.39 Popular NIH Departments: Distribution by Number of Grants
Table 14.40 Prominent Program Officers: Distribution by Number of Grants
Table 14.41 Popular Recipient Organizations: Distribution by Number of Grants
Table 14.42 Publication Analysis: Cumulative Year-wise Trend, Since 2010
Table 14.43 Publication Analysis: Distribution by Target Therapeutic Area
Table 14.44 Leading Authors: Distribution by Number of Publications
Table 14.45 Key Journals: Distribution by Number of Publications
Table 14.46 Patent Analysis: Distribution by Publication Year
Table 14.47 Patent Analysis: Distribution by Type of Patent
Table 14.48 Patent Analysis: Distribution by Geographical Location
Table 14.49 Patent Analysis: Distribution by Patent Age
Table 14.50 Patent Analysis: Distribution by CPC Symbols
Table 14.51 Leading Patent Assignees: Distribution by Number of Patents
Table 14.52 Leading Industry Players: Distribution by Number of Patents
Table 14.53 Patent Analysis: Distribution by Patent Benchmarking
Table 14.54 Patent Analysis: Distribution by Patent Valuation
Table 14.55 Partnerships and Collaborations: Cumulative Year-wise Trend, Since 2015
Table 14.56 Partnerships and Collaborations: Distribution by Type of Partnership
Table 14.57 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Fusion Molecule
Table 14.58 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Table 14.59 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Table 14.60 Most Active Players: Distribution by Number of Partnerships
Table 14.61 Partnerships and Collaborations: Regional Distribution
Table 14.62 Global Fc Fusion Therapeutics Market, Till 2035 (USD Million)
Table 14.63 Global Fc Fusion Therapeutics Market, Till 2035: Distribution by Target Indication (USD Million)
Table 14.64 Global Fc Fusion Therapeutics Market, Till 2035: Distribution by Type of Therapy (USD Million)
Table 14.65 Global Fc Fusion Therapeutics Market, Till 2035: Distribution by Route of Administration (USD Million
Table 14.66 Global Fc Fusion Therapeutics Market, Till 2035: Distribution by Geography (USD Million)
Table 14.67 ABP 938: Sales Forecast, Till 2035 (USD Million)
Table 14.68 Alprolix(R): Sales Forecast, Till 2035 (USD Million)
Table 14.69 AnBaiNuo(R): Sales Forecast, Till 2035 (USD Million)
Table 14.70 Arcalyst(R): Sales Forecast, Till 2035 (USD Million)
Table 14.71 BIVV001: Sales Forecast, Till 2035 (USD Million)
Table 14.72 CD24Fc: Sales Forecast, Till 2035 (USD Million)
Table 14.73 Eloctate(R): Sales Forecast, Till 2035 (USD Million)
Table 14.74 Eylea(TM): Sales Forecast, Till 2035 (USD Million)
Table 14.75 FRSW107: Sales Forecast, Till 2035 (USD Million)
Table 14.76 KN035: Sales Forecast, Till 2035 (USD Million)
Table 14.77 KN046: Sales Forecast, Till 2035 (USD Million)
Table 14.78 Lumitin(R): Sales Forecast, Till 2035 (USD Million)
Table 14.79 Reblozyl(R): Sales Forecast, Till 2035 (USD Million)
Table 14.80 RyzneutaTM: Sales Forecast, Till 2035 (USD Million)
Table 14.81 Strensiq(R): Sales Forecast, Till 2035 (USD Million)
Table 14.82 Telitacicept: Sales Forecast, Till 2035 (USD Million)
Table 14.83 Fc Protein Engineered and Glycoengineered Antibodies: Analysis by Phase of Development
Table 14.84 Fc Protein Engineered and Glycoengineered Antibodies: Analysis by Target Disease Indication
Table 14.85 Fc Protein Engineered and Glycoengineered Antibodies: Analysis by Therapeutic Area
Table 14.86 Fc Protein Engineered and Glycoengineered Antibodies: Analysis by Type of Fc Engineering
Table 14.87 Fc Protein Engineered and Glycoengineered Antibodies: Analysis by Impact of Fc Engineering
Table 14.88 Fc Protein Engineered and Glycoengineered Antibodies: Analysis by Route of Administration
Table 14.89 Fc Protein Engineered and Glycoengineered Antibodies: Analysis by Type of Therapy
Table 14.90 Fc Protein Engineered and Glycoengineered Antibodies Developers: Analysis by Year of Establishment
Table 14.91 Fc Protein Engineered and Glycoengineered Antibodies Developers Analysis by Company Size
Table 14.92 Fc Protein Engineered and Glycoengineered Antibodies Developers Analysis by Location of Headquarters

List of Figures

Figure 2.1 Executive Summary: Overall Market Landscape
Figure 2.2 Executive Summary: Clinical Trial Analysis
Figure 2.3 Executive Summary: Academic Grant Analysis
Figure 2.4 Executive Summary: Publication Analysis
Figure 2.5 Executive Summary: Patent Analysis
Figure 2.6 Executive Summary: Partnerships and Collaborations
Figure 2.7 Executive Summary: Market Forecast
Figure 3.1 Components of Fc Fusion Therapeutics
Figure 3.2 Mechanism of Action
Figure 4.1 Fc Fusion Therapeutics: Distribution by Phase of Development
Figure 4.2 Fc Fusion Therapeutics: Distribution by Type of Fusion Molecule
Figure 4.3 Fc Fusion Therapeutics: Distribution by Target Gene
Figure 4.4 Fc Fusion Therapeutics: Distribution by Therapeutic Area(s)
Figure 4.5 Fc Fusion Therapeutics: Distribution by Target Disease Indication(s)
Figure 4.6 Fc Fusion Therapeutics: Distribution by Type of Therapy
Figure 4.7 Fc Fusion Therapeutics: Distribution by Route of Administration
Figure 4.8 Fc Fusion Therapeutics: Distribution by Dosing Frequency
Figure 4.9 Fc Fusion Therapeutics Developers: Distribution by Year of Establishment
Figure 4.10 Fc Fusion Therapeutics Developers: Distribution by Company Size
Figure 4.11 Fc Fusion Therapeutics Developers: Distribution by Location of Headquarters
Figure 4.12 Leading Developers: Distribution by Number of Fc Fusion Therapeutics
Figure 4.13 Grid Analysis: Distribution by Phase of Development, Company Size and Location of Headquarters
Figure 5.1 Amgen: Annual Revenues, Since 2016 (USD Billion)
Figure 5.2 Acceleron Pharmaceuticals: Annual Revenues, Since 2016 (USD Billion)
Figure 5.3 Bristol Myers Squibb: Annual Revenues, Since 2016 (USD Billion)
Figure 5.4 Sanofi: Annual Revenues, Since 2016 (USD Billion)
Figure 6.1 Clinical Trial Analysis: Distribution by Trial Registration Year
Figure 6.2 Clinical Trial Analysis: Distribution by Trial Phase
Figure 6.3 Clinical Trial Analysis: Distribution by Study Design
Figure 6.4 Clinical Trial Analysis: Distribution by Type of Masking
Figure 6.5 Clinical Trial Analysis: Distribution by Type of Intervention Model
Figure 6.6 World Cloud Analysis: Emerging Focus Areas
Figure 6.7 Clinical Trial Analysis: Distribution by Trial Registration Year and Geography
Figure 6.8 Clinical Trial Analysis: Distribution by Type of Sponsor
Figure 6.9 Leading Industry Players: Distribution by Number of Trials Registered
Figure 6.10 Leading Non-Industry Players: Distribution by Number of Trials Registered
Figure 6.11 Popular Indications: Distribution by Number of Registered Trials
Figure 6.12 Popular Interventions: Distribution by Number of Registered Trials
Figure 6.13 Popular Indications: Distribution by Number of Registered Trials
Figure 6.14 Popular Interventions: Distribution by Number of Registered Trials
Figure 6.15 Clinical Trial Analysis: Geographical Distribution by Number of Registered Trials
Figure 6.16 Clinical Trial Analysis: Geographical Distribution by Number of Patients Enrolled
Figure 7.1 Grant Analysis: Cumulative Trend by Year of Grant Award, Since 2010
Figure 7.2 Grant Analysis: Cumulative Distribution by Amount Awarded (USD Million), Since 2010
Figure 7.3 Grant Analysis: Distribution by Administering Institute Center
Figure 7.4 Grant Analysis: Distribution by Support Period
Figure 7.5 Grant Analysis: Distribution by Type of Grant Application
Figure 7.6 Grant Analysis: Distribution by Purpose of Grant Award
Figure 7.7 Grant Analysis: Distribution by Activity Code
Figure 7.8 Word Cloud Analysis: Emerging Focus Areas
Figure 7.9 Popular NIH Departments: Distribution by Number of Grants
Figure 7.10 Prominent Program Officers: Distribution by Number of Grants
Figure 7.11 Popular Recipient Organizations: Distribution by Number of Grants
Figure 8.1 Publication Analysis: Cumulative Year-wise Trend, Since 2010
Figure 8.2 Word Cloud Analysis: Emerging Focus Areas
Figure 8.3 Publication Analysis: Distribution by Target Therapeutic Area
Figure 8.4 Leading Authors: Distribution by Number of Publications
Figure 8.5 Key Journals: Distribution by Number of Publications
Figure 9.1 Patent Analysis: Distribution by Publication Year
Figure 9.2 Patent Analysis: Distribution by Type of Patent
Figure 9.3 Patent Analysis: Distribution by Geographical Location
Figure 9.4 Patent Analysis: Distribution by Patent Age
Figure 9.5 Patent Analysis: Distribution by CPC Symbols
Figure 9.6 Word Cloud Analysis: Emerging Focus Areas
Figure 9.7 Leading Patent Assignees: Distribution by Number of Patents
Figure 9.8 Leading Industry Players: Distribution by Number of Patents
Figure 9.9 Leading Non-Industry Players: Distribution by Number of Patents
Figure 9.10 Patent Analysis: Distribution by Patent Benchmarking
Figure 9.11 Patent Analysis: Distribution by Patent Valuation
Figure 10.1 Partnerships and Collaborations: Cumulative Year-wise Trend, Since 2015
Figure 10.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 10.3 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Fusion Molecule
Figure 10.4 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Figure 10.5 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Figure 10.6 Most Active Players: Distribution by Number of Partnerships
Figure 10.7 Partnerships and Collaborations: Regional Distribution

Figure 10.7.1 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements

Figure 11.1 Global Fc Fusion Therapeutics Market, Till 2035 (USD Million)
Figure 11.2 Global Fc Fusion Therapeutics Market, Till 2035: Distribution by Target Indication (USD Million)
Figure 11.3 Global Fc Fusion Therapeutics Market, Till 2035: Distribution by Type of Fusion Molecule (USD Million)
Figure 11.4 Global Fc Fusion Therapeutics Market, Till 2035: Distribution by Type of Therapy (USD Million)
Figure 11.5 Global Fc Fusion Therapeutics Market, Till 2035: Distribution by Route of Administration (USD Million
Figure 11.6 Global Fc Fusion Therapeutics Market, Till 2035: Distribution by Geography (USD Million)
Figure 11.7 ABP 938: Sales Forecast, Till 2035 (USD Million)
Figure 11.8 Alprolix(R): Sales Forecast, Till 2035 (USD Million)
Figure 11.9 AnBaiNuo(R): Sales Forecast, Till 2035 (USD Million)
Figure 11.10 Arcalyst(R): Sales Forecast, Till 2035 (USD Million)
Figure 11.11 BIVV001: Sales Forecast, Till 2035 (USD Million)
Figure 11.12 CD24Fc: Sales Forecast, Till 2035 (USD Million)
Figure 11.13 Eloctate(R): Sales Forecast, Till 2035 (USD Million)
Figure 11.14 Eylea(TM): Sales Forecast, Till 2035 (USD Million)
Figure 11.15 FRSW107: Sales Forecast, Till 2035 (USD Million)
Figure 11.16 KN035: Sales Forecast, Till 2035 (USD Million)
Figure 11.17 KN046: Sales Forecast, Till 2035 (USD Million)
Figure 11.18 Lumitin(R): Sales Forecast, Till 2035 (USD Million)
Figure 11.19 Reblozyl(R): Sales Forecast, Till 2035 (USD Million)
Figure 11.20 RyzneutaTM: Sales Forecast, Till 2035 (USD Million)
Figure 11.21 Strensiq(R): Sales Forecast, Till 2035 (USD Million)
Figure 11.21 Telitacicept: Sales Forecast, Till 2035 (USD Million)
Figure 12.1 Fc Protein Engineered and Glycoengineered Antibodies: Analysis by Phase of Development
Figure 12.2 Fc Protein Engineered and Glycoengineered Antibodies: Analysis by Target Disease Indication
Figure 12.3 Fc Protein Engineered and Glycoengineered Antibodies: Analysis by Therapeutic Area
Figure 12.4 Fc Protein Engineered and Glycoengineered Antibodies: Analysis by Type of Fc Engineering
Figure 12.5 Fc Protein Engineered and Glycoengineered Antibodies: Analysis by Impact of Fc Engineering
Figure 12.6 Fc Protein Engineered and Glycoengineered Antibodies: Analysis by Route of Administration
Figure 12.7 Fc Protein Engineered and Glycoengineered Antibodies: Analysis by Type of Therapy
Figure 12.8 Fc Protein Engineered and Glycoengineered Antibodies Developers: Analysis by Year of Establishment
Figure 12.9 Fc Protein Engineered and Glycoengineered Antibodies Developers Analysis by Company Size
Figure 12.10 Fc Protein Engineered and Glycoengineered Antibodies Developers Analysis by Location of Headquarters
Figure 13.1 Concluding Remarks: Overall market Landscape
Figure 13.2 Concluding Remarks: Clinical Trial Analysis
Figure 13.3 Concluding Remarks: Academic Grants Analysis
Figure 13.4 Concluding Remarks: Publication Analysis
Figure 13.5 Concluding Remarks: Patent Analysis
Figure 13.6 Concluding Remarks: Partnerships and Collaborations
Figure 13.7 Concluding Remarks: Market Forecast

Fc Fusion Protein Market: Industry Trends and Global Forecasts - Distribution by Target Indications, Type of Fusion Molecule, Route of Administration and Key Geographical Regions

Description

Table of Contents

List of Tables

GLOBAL FC FUSION PROTEIN MARKET: OVERVIEW

GLOBAL FC FUSION PROTEIN MARKET: GROWTH AND TRENDS

GLOBAL FC FUSION PROTEIN MARKET: KEY INSIGHTS

Example Players in the Drug Discovery Platforms Market

GLOBAL FC FUSION PROTEIN MARKET

KEY QUESTIONS ANSWERED IN THIS REPORT

REASONS TO BUY THIS REPORT

ADDITIONAL BENEFITS

TABLE OF CONTENTS

1. PREFACE

2. EXECUTIVE SUMMARY

3. INTRODUCTION

4. PIPELINE REVIEW: MARKETED AND CLINICAL DRUGS

5. COMPANY PROFILES

6. CLINICAL TRIAL ANALYSIS

7. ACADEMIC GRANT ANALYSIS

8. PUBLICATION ANALYSIS

9. PATENT ANALYSIS

10. PARTNERSHIPS AND COLLABORATIONS

11. MARKET SIZING AND OPPORTUNITY ANALYSIS

12. CASE STUDY: FC PROTEIN ENGINEERED AND GLYCOENGINEERED ANTIBODIES

13. CONCLUSION

14. APPENDIX 1: TABULATED DATA

15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Tables

List of Figures